KE

Kimball Electronics, Inc.
7 filings tracked
technologycloud computingSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Kimball Electronics is demonstrating a sophisticated transition from a volume-centric manufacturer to a profitability-focused solutions provider.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The recent surge in Kimball's profitability may be more illusory than sustainable, as much of the bottom-line growth stems from one-time restructuring actions rather than organic demand.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every KE filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest filing reveals a company at a critical inflection point, attempting to trade scale for efficiency. The synthesis of the data shows a business that has successfully deleveraged and improved its cash conversion cycle, yet remains vulnerable to the same macroeconomic pressures that have historically plagued the EMS industry. The successful extension of the primary credit facility to 2031 provides the necessary breathing room for the company to execute its 'Kimball Solutions' rebranding and strategic pivot. Ultimately, the investment thesis hinges on whether the medical vertical can scale sufficiently to offset the cyclicality of the automotive and industrial markets. While the immediate financial results are impressive, the long-term trajectory will be determined by the company's ability to convert its new capacity in Indianapolis into sustainable, high-margin revenue streams without further relying on one-time restructuring gains.

Selected Quarter

Core Takeaway

Kimball is successfully expanding margins and reducing debt, but organic growth is stalling as the customer base shrinks.

Investor Lens

The trade-off is between a lean, highly profitable 'small' company versus a growth-oriented manufacturer that is currently losing market share.

Watch Next

The ramp-up of the new Indianapolis medical facility and the impact of the 'Kimball Solutions' rebranding on new customer wins.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.75Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%
bullishMay 6

Gross margins expanded from 6.7% to 8.0% year-to-date.

margin expansion
90%
bullishMay 6

Net income grew 87% year-over-year despite falling sales.

earnings beat
80%
bullishMay 6

Repurchased $113.5 million of common stock under authorized plan.

buyback
70%
bullishMay 6

Extended primary credit facility maturity to 2031.

debt restructure
60%

Filing History

10-QMay 6, 2026
Expand Sequence

The latest filing reveals a company at a critical inflection point, attempting to trade scale for efficiency. The synthesis of the data shows a business that has successfully deleveraged and improved its cash conversion cycle, yet remains vulnerable to the same macroeconomic pressures that have historically plagued the EMS industry. The successful extension of the primary credit facility to 2031 provides the necessary breathing room for the company to execute its 'Kimball Solutions' rebranding and strategic pivot. Ultimately, the investment thesis hinges on whether the medical vertical can scale sufficiently to offset the cyclicality of the automotive and industrial markets. While the immediate financial results are impressive, the long-term trajectory will be determined by the company's ability to convert its new capacity in Indianapolis into sustainable, high-margin revenue streams without further relying on one-time restructuring gains.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.